Cargando…

Fenofibrate improves endothelial function and plasma myeloperoxidase in patients with type 2 diabetes mellitus: an open-label interventional study

BACKGROUND: Fenofibrate offers a number of benefits on the cardiovascular system and it is plausible that its anti-inflammatory, anti-oxidant and anti-fibrotic effects and enhancement of cardiac metabolic performances may account for its direct cardioprotective effects. In this study we aimed to inv...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nita, Cristina, Bala, Cornelia, Porojan, Mihai, Hancu, Nicolae
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3974011/ https://www.ncbi.nlm.nih.gov/pubmed/24594096 http://dx.doi.org/10.1186/1758-5996-6-30

Ejemplares similares

The role of NOS2A −954G/C and vascular endothelial growth factor +936C/T polymorphisms in type 2 diabetes mellitus and diabetic nonproliferative retinopathy risk management
por: Porojan, Mihai Dumitru, et al.
Publicado: (2015)

Combined glutathione S transferase M1/T1 null genotypes is associated with type 2 diabetes mellitus
por: POROJAN, MIHAI D., et al.
Publicado: (2015)

Comparison of efficacy and safety of choline fenofibrate (fenofibric acid) to micronized fenofibrate in patients of mixed dyslipidemia: A randomized, open-label, multicenter clinical trial in Indian population
por: Patel, Piyush, et al.
Publicado: (2016)

Effect of the early intensive multifactorial therapy on the cardiovascular risk in patients with newly diagnosed type 2 diabetes: an observational, prospective study
por: STEFAN, RAMONA MARIA, et al.
Publicado: (2015)

Fenofibrate improves vascular endothelial function and contractility in diabetic mice
por: Xu, Nan, et al.
Publicado: (2018)

The Efficacy of Fenofibrate in Addition to Atorvastatin in Patients of Type II Diabetes Mellitus
por: Qasim, Muhammad, et al.
Publicado: (2022)

Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: baseline characteristics and short-term effects of fenofibrate [ISRCTN64783481]
Publicado: (2005)

Myeloperoxidase inhibition may protect against endothelial glycocalyx shedding induced by COVID-19 plasma
por: Teo, Andrew, et al.
Publicado: (2023)

A myeloperoxidase precursor, pro-myeloperoxidase, is present in human plasma and elevated in cardiovascular disease patients
por: Khalilova, Irada S., et al.
Publicado: (2018)

Endothelial Function in a Mouse Model of Myeloperoxidase Deficiency
por: Golubinskaya, Veronika, et al.
Publicado: (2014)

Pharmacokinetic interactions and tolerability of berberine chloride with simvastatin and fenofibrate: an open-label, randomized, parallel study in healthy Chinese subjects
por: Li, Guofei, et al.
Publicado: (2018)

A Review of Currently Available Fenofibrate and Fenofibric Acid Formulations
por: Ling, Hua, et al.
Publicado: (2013)

Comparison of Efficacy and Safety of Fixed Dose Combination of Rosuvastatin and Choline Fenofibrate to Fixed Dose Combination of Rosuvastatin and Fenofibrate in Patients of Mixed Dyslipidemia: A Randomized, Open-label, Multicentre Clinical Trial in Indian Population
por: Barkate, Hanmant, et al.
Publicado: (2018)

Achievement of Lipid Targets with the Combination of Rosuvastatin and Fenofibric Acid in Patients with Type 2 Diabetes Mellitus
por: Rosenson, Robert S., et al.
Publicado: (2010)

Fenofibrate Treatment Enhances Antioxidant Status and Attenuates Endothelial Dysfunction in Streptozotocin-Induced Diabetic Rats
por: Olukman, Murat, et al.
Publicado: (2010)

Development and validation of bioanalytical UHPLC-UV method for simultaneous analysis of unchanged fenofibrate and its metabolite fenofibric acid in rat plasma: Application to pharmacokinetics
por: Alamri, Rayan G., et al.
Publicado: (2017)

Decreased Plasma Myeloperoxidase Associated with Probiotic Therapy in Autistic Children
por: Russo, Anthony J.
Publicado: (2015)

Low-density lipoprotein modified by myeloperoxidase oxidants induces endothelial dysfunction
por: Abdo, Adrian I., et al.
Publicado: (2017)

Effect of myeloperoxidase modified LDL on bovine and human aortic endothelial cells
por: El Samad, Ghadir, et al.
Publicado: (2019)

Endothelial Cell Protein Targeting by Myeloperoxidase-Derived 2-Chlorofatty Aldehyde
por: Shakya, Shubha, et al.
Publicado: (2022)

Elevated plasma free fatty acids increase cardiovascular risk by inducing plasma biomarkers of endothelial activation, myeloperoxidase and PAI-1 in healthy subjects
por: Mathew, Manoj, et al.
Publicado: (2010)

Vascular Endothelium as a Target of Beraprost Sodium and Fenofibrate for Antiatherosclerotic Therapy in Type 2 Diabetes Mellitus
por: Otsuki, Michio, et al.
Publicado: (2005)

Therapeutic Effects of Fenofibrate on Diabetic Peripheral Neuropathy by Improving Endothelial and Neural Survival in db/db Mice
por: Cho, Ye Rim, et al.
Publicado: (2014)

Myeloperoxidase G-463A and CYBA C242T genetic variants in gestational diabetes mellitus
por: Jiang, Chenyu, et al.
Publicado: (2023)

A review on the rationale and clinical use of concomitant rosuvastatin and fenofibrate/fenofibric acid therapy
por: Strain, Joe D, et al.
Publicado: (2010)

Effects of Fenofibrate Treatment on Cardiovascular Disease Risk in 9,795 Individuals With Type 2 Diabetes and Various Components of the Metabolic Syndrome: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study
por: Scott, Russell, et al.
Publicado: (2009)

Cytotoxicity towards human endothelial cells, induced by neutrophil myeloperoxidase: protection by ceftazidime
por: Mathy-Hartert, M., et al.
Publicado: (1995)

Neutrophil-derived microparticles induce myeloperoxidase-mediated damage of vascular endothelial cells
por: Pitanga, Thassila Nogueira, et al.
Publicado: (2014)

A rapid bioluminescence assay for measuring myeloperoxidase activity in human plasma
por: Goiffon, Reece J., et al.
Publicado: (2015)

Fibrane the reduced derivative of fenofibrate
por: Kotheimer, Amanda E., et al.
Publicado: (2019)

Myeloperoxidase in Health and Disease
por: Ortiz-Cerda, Tamara, et al.
Publicado: (2023)

Association of Plasma Myeloperoxidase Level with Risk of Coronary Artery Disease in Patients with Type 2 Diabetes
por: Song, Ping, et al.
Publicado: (2015)

Effects of fenofibrate on inflammatory cytokines in diabetic retinopathy patients
por: Ju, Hai-Bing, et al.
Publicado: (2017)

Fenofibrate and Impaired Taste Perception in Type 2 Diabetes
por: Davis, Timothy M.E.
Publicado: (2020)

Exposure of Endothelial Cells to Physiological Levels of Myeloperoxidase-Modified LDL Delays Pericellular Fibrinolysis
por: Zouaoui Boudjeltia, Karim, et al.
Publicado: (2012)

Myeloperoxidase and related biomarkers are suggestive footprints of endothelial microvascular inflammation in HFpEF patients
por: Hage, Camilla, et al.
Publicado: (2020)

Association of Myeloperoxidase and the Atherogenic Index of Plasma in Children with End-Stage Renal Disease
por: Ristovski-Kornic, Danijela, et al.
Publicado: (2017)

Significance of myeloperoxidase plasma levels as a predictor for cardiac resynchronization therapy response
por: Sultan, A., et al.
Publicado: (2020)

Plasma myeloperoxidase: association with atrial fibrillation progression and recurrence after catheter ablation
por: Liu, Jingmeng, et al.
Publicado: (2023)

Neither polyphenol-rich red wine nor fenofibrate affects the onset of type-1 diabetes mellitus in the BB rat
por: Åvall, Karin, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_86hiovedunrqkkinf80hfp011p